A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China

Abstract

Hyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy but it has severe side-effects. HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. In this retrospective report, we had genotyped HLA-B*5801 in 253 cases of hyperuricemia and gout patients in a Han population in Shenzhen and analyzed the clinical management of medications. We found 30 carriers of HLA-B*5801 allele in 253 cases of hyperuricemia or gout patients in the population (11.9%). Allopurinol was prescribed in both HLA-B*5801 positive and negative groups. The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated the HLA-B*5801 screening had significant cost benefit for clinical management. HLA-B*5801 allele should be screened in all patients with hyperuiciemia and gout in the Chinese population.